Nima Farzan, Kinnate CEO

Kin­nate gets $98M Se­ries C to push pre­ci­sion on­col­o­gy drugs to the clin­ic

Less than a year af­ter bank­ing $74.5 mil­lion in a Se­ries B, San Diego-based Kin­nate Bio­phar­ma is fol­low­ing up with a Se­ries C to bring its pipeline of pre­ci­sion on­col­o­gy drugs to the clin­ic.

The two-year-old com­pa­ny just raised $98 mil­lion in a round led by RA Cap­i­tal Man­age­ment, and is eye­ing INDs for its two lead pro­grams — ki­nase in­hibitors that tar­get BRAF, FGFR2 and FGFR3 mu­ta­tions. If all goes well in pre­clin­i­cal stud­ies, CEO Ni­ma Farzan ex­pects its BRAF pro­gram to en­ter Phase I in the first half of next year, with its FGFR pro­gram not far be­hind.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters